Bluebird bio and Carlyle Group and SK Capital Partners said on Wednesday that the private equity firms have offered $5 per share upfront to takeover the gene therapy maker.
Shareholders may elect to receive either the new offer or the previous offer of $3 per share, with an additional $6.84 contingent upon bluebird achieving certain sales milestones.
https://finance.yahoo.com/news/bluebird-bio-receives-higher-upfront-125148001.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.